Gilead Sciences, Inc. (LON:0QYQ)
121.10
+1.45 (1.21%)
At close: Nov 3, 2025
Gilead Sciences Revenue
Gilead Sciences had revenue of $7.77B USD in the quarter ending September 30, 2025, with 2.97% growth. This brings the company's revenue in the last twelve months to $29.09B, up 2.78% year-over-year. In the year 2024, Gilead Sciences had annual revenue of $28.75B with 6.04% growth.
Revenue (ttm)
$29.09B
Revenue Growth
+2.78%
P/S Ratio
5.33
Revenue / Employee
$1.65M
Employees
17,600
Market Cap
115.31B GBP
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 28.75B | 1.64B | 6.04% |
| Dec 31, 2023 | 27.12B | -165.00M | -0.60% |
| Dec 31, 2022 | 27.28B | -24.00M | -0.09% |
| Dec 31, 2021 | 27.31B | 2.62B | 10.60% |
| Dec 31, 2020 | 24.69B | 2.24B | 9.98% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Shell | 200.18B |
| BP p.l.c. | 140.08B |
| Unilever | 51.24B |
| HSBC Holdings | 43.13B |
| AstraZeneca | 41.24B |
| Rio Tinto Group | 39.22B |
| GSK plc | 32.17B |
| British American Tobacco p.l.c. | 25.60B |